top of page
Search
An Australian Optometrist’s Perspective on Choosing Myopia Treatment
An Australian Optometrist’s Perspective on Choosing Myopia Treatment
Dr Mark Joung
12 hours ago5 min read
"Wow, Everyone Else Can See Like This”
I recently came across Dr David Hunter’s LinkedIn post about about his Washington Post piece on the FDA’s October 2025 decision to reject SYD-101, a low-dose atropine treatment for progressive childhood myopia. The article focused on the confusing regulatory reasoning — behind the decision not to license SYD-101 in the US. On face value, it is confusing!
Richard Kadri-Langford
Feb 163 min read
bottom of page